Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Macitentan
Drug ID BADD_D01336
Description Macitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension.[L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] due to its lower risk of hepatotoxicity.
Indications and Usage Macitentan is indicated for the treatment of WHO group 1 pulmonary arterial hypertension (PAH) both alone and in combination with tadalafil.[L39105, L39105]
Marketing Status approved
ATC Code C02KX04
DrugBank ID DB08932
KEGG ID D10135
MeSH ID C533860
PubChem ID 16004692
TTD Drug ID D0S7JH
NDC Product Code 65015-872; 11722-058; 66215-501; 68225-070; 69037-0030; 76397-014; 59651-122; 82245-0117; 69766-006
UNII Z9K9Y9WMVL
Synonyms macitentan | N-(5-(4-bromophenyl)-6-(2-(5-bromopyrimidin-2-yloxy)ethoxy)pyrimidin-4-yl)-N'-propylaminosulfonamide | ACT 064992 | ACT064992 | ACT-064992 | Actelion-1 | opsumit
Chemical Information
Molecular Formula C19H20Br2N6O4S
CAS Registry Number 441798-33-0
SMILES CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Small intestinal obstruction07.13.06.0010.001083%
Sneezing22.12.03.0240.001613%
Spinal cord compression17.10.01.0060.000120%
Sputum discoloured22.02.03.0100.001673%Not Available
Stress19.06.02.0040.002936%Not Available
Sudden death08.04.01.003; 02.03.04.0130.000662%
Suffocation feeling22.12.02.0140.000241%Not Available
Supraventricular tachycardia02.03.03.0120.000770%
Swelling08.01.03.0150.020976%Not Available
Swelling face08.01.03.100; 10.01.05.018; 23.04.01.0180.003358%Not Available
Syncope24.06.02.012; 17.02.04.008; 02.11.04.0150.009110%
Systemic lupus erythematosus23.03.02.006; 15.06.02.003; 10.04.03.0040.001203%Not Available
Telangiectasia24.03.03.003; 23.06.03.0010.000120%
Thinking abnormal19.10.03.001; 17.02.05.0230.000794%Not Available
Throat irritation22.12.03.029; 07.05.05.0370.004248%Not Available
Thyroid disorder05.02.01.0020.000626%Not Available
Toothache07.09.06.0010.001733%
Tympanic membrane perforation12.01.14.001; 04.05.04.0010.000265%Not Available
Unresponsive to stimuli17.02.05.0310.001288%Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Uterine cancer21.07.02.003; 16.12.05.0010.000241%Not Available
Uterine leiomyoma21.07.02.004; 16.04.02.0010.000915%Not Available
Varicose vein24.10.04.0010.000590%Not Available
Vascular pain24.03.02.0260.000409%Not Available
Ventricular tachycardia02.03.04.0100.000542%
Volvulus07.13.01.0120.000181%Not Available
Vulvovaginal discomfort21.08.02.0050.000409%Not Available
Wheezing22.03.01.0090.003105%
Yellow skin23.03.03.042; 09.01.01.009; 08.01.03.0460.000939%Not Available
Mental status changes19.07.01.0010.001589%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 16 Pages